Allogene Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Allogene Therapeutics (ALLO).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

2S.Buy

10Buy

6Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$8Upside to Avg. PT+514.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$6
Apr 16, 2026	JP Morgan	Brian Cheng	Upgrade	Underweight→Neutral	—
Apr 16, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$12→$11
Apr 15, 2026	Jefferies	Roger Song	PT Raise	Buy	$6→$10
Apr 14, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$2→$4
Apr 14, 2026	Argus Research	William Pickering	PT Raise	Market Perform	$2→$4
Apr 14, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$5→$8
Apr 14, 2026	Baird	Jack Allen	PT Raise	Outperform	$7→$9
Apr 14, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$8→$12
Mar 13, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$14
Mar 13, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$7→$8
Jan 9, 2026	Citizens	Reni Benjamin	Upgrade	Market Perform→Market Outperform	$5
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$8
Oct 10, 2025	JP Morgan	Brian Cheng	Downgrade	Neutral→Underweight	—
Aug 4, 2025	JMP Securities	Reni Benjamin	Maintained	Market Perform	—
Aug 4, 2025	JP Morgan	Brian Cheng	Downgrade	Overweight→Neutral	—
Aug 1, 2025	Oppenheimer	Mark Breidenbach	PT Cut	Outperform	$9→$7
May 15, 2025	Citigroup	Samantha Semenkow	PT Cut	Buy	$8→$4
May 14, 2025	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$14→$10
May 14, 2025	Piper Sandler	Biren Amin	PT Cut	Overweight	$9→$7

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.

Benzinga Newsdesk

PRO
JP Morgan Upgrades Allogene Therapeutics to Neutral

JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Underweight to Neutral.

Benzinga Newsdesk

Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham raises TSM PT, HC Wainwright slashes ALLO PT, Goldman raises MS PT, Baird raises WM PT, Bernstein raises INTC PT, B of A raises PNC PT.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $12 to $11.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target from $6 to $10.

Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Perform and raises the price target from $1.6 to $3.85.

Benzinga Newsdesk

Allogene Therapeutics Inc

Allogene Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

PRO
JP Morgan Upgrades Allogene Therapeutics to Neutral

Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

PRO
Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

PRO
Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

People Also Watch

People Also Watch

Allogene Therapeutics Inc

Allogene Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

PROJP Morgan Upgrades Allogene Therapeutics to Neutral

Dell To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday

PROHC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

PROJefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

PROBernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target

PRO
JP Morgan Upgrades Allogene Therapeutics to Neutral

PRO
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

PRO
Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

PRO
Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85